Design Therapeutics (DSGN) Accounts Payables (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Accounts Payables of $3.1 million for Q2 2026, up 210.07% year-over-year from $1.0 million in Q2 2025, and up 38.01% on a QoQ basis from $2.3 million in Q1 2026.
Design Therapeutics (DSGN) Accounts Payables (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $3.1 million in Q2 2026.
- Accounts Payables for Q2 2026 came in at $3.1 million, up 210.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.1 million (up 210.07% YoY), and the FY2025 annual result was $2.3 million, up 5.76% from the prior year.
- Accounts Payables rose to $3.1 million in Q2 2026, from $2.3 million in the prior quarter.
- Over five years, Accounts Payables peaked at $3.2 million in Q1 2025 and troughed at $1.0 million in Q2 2025.
- A 5-year average of $2.1 million and a median of $2.1 million in 2022 frame the typical range for Accounts Payables.
- The widest annual swing landed in 2024, when Accounts Payables plunged 50.0%; it then jumped 210.07% in 2026.
- A 5-year view of Accounts Payables shows it stood at $3.0 million in 2022, then slumped by 35.87% to $1.9 million in 2023, then gained by 12.68% to $2.2 million in 2024, then gained by 5.76% to $2.3 million in 2025, then jumped by 35.86% to $3.1 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $3.1 million in Q2 2026, $2.3 million in Q1 2026, and $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.14 Mn |
| Mar 31, 2026 | 2.28 Mn |
| Dec 31, 2025 | 2.31 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Dec 31, 2024 | 2.19 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Sep 30, 2023 | 2.21 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 2.74 Mn |
| Dec 31, 2022 | 3.03 Mn |
| Sep 30, 2022 | 2.62 Mn |
| Jun 30, 2022 | 2.07 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Dec 31, 2021 | 1.62 Mn |
| Sep 30, 2021 | 2.22 Mn |